BIIB Company Profile and Key Details

Q: Who are the executives of BIIB?

Ms. Nicole MurphyHead of Pharmaceutical Operations & TechnologyDr. Sanjay JariwalaSenior Vice President of Worldwide MedicalMs. Robin C. KramerSenior Vice President & Chief Accounting OfficerMr. Adam Keeney Ph.D.Executive Vice President & Head of Corporation Devel.Dr. Anabella Villalobos Ph.D.Head of Biotherapeutics & Medicinal SciencesDr. Mahalakshmi Radhakrishnan M.D.Chief Medical Officer & Group Senior Vice PresidentMs. Natacha GassenbachChief Communication Officer & Head of Corporation AffairsDr. Ginger GregoryExecutive Vice President & Chief HR OfficerMr. Christopher A. ViehbacherPres, Chief Executive Officer & DirectorMr. Michael R. McDonnell CPAExecutive Vice President & Chief Financial OfficerMr. Michael HenckeExecutive Director of Investor Relations & Investor Relations TeamMr. Charles E. TrianoSenior Vice President & Head of Investor RelationsMs. Susan H. Alexander Esq.Executive Vice President, Chief Legal Officer & Sec.Dr. Priya Singhal M.D., M.P.H.Executive Vice President, Head of Devel. and Interim Head of Research, Global Safety & Regulatory SciencesMs. Alisha A. AlaimoPres & Head of North America

NASDAQ : BIIB

Biogen

$174.80

4.89+2.88%

At Close 4:00 PM

70.86

B+ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Biogen Inc. (BIIB) stock declined over -0.06%, trading at $174.70 on NASDAQ, down from the previous close of $174.80. The stock opened at $174.78, fluctuating between $172.90 and $177.29 in the recent session.

Stock Snapshot

174.8

Prev. Close

25.63B

Market Cap

172.9

Day Low

15.91

P/E Ratio

10.98

EPS (TTM)

9.99

Cash Flow per Share

174.78

Open

146.7M

Number of Shares

177.29

Day High

99.74%

Free Float in %

110.12

Book Value

1.7M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 19, 2025	171.32	176.42	170.00	174.80	14.87M
Dec 17, 2025	171.43	173.83	169.55	172.10	2.76M
Dec 16, 2025	174.51	174.51	169.52	171.50	2.38M
Dec 15, 2025	173.67	175.94	170.45	175.74	2.25M
Dec 12, 2025	173.49	175.08	171.27	174.10	1.74M
Dec 11, 2025	177.47	180.79	172.00	172.50	2.72M
Dec 10, 2025	173.30	178.17	169.24	177.55	2.13M
Dec 09, 2025	179.91	181.99	175.39	175.84	1.51M
Dec 08, 2025	181.30	182.12	179.21	180.44	1.47M
Dec 05, 2025	181.96	183.15	181.10	181.30	1.18M
Dec 04, 2025	181.86	182.69	179.27	181.98	1.23M
Dec 03, 2025	180.17	182.94	178.16	180.75	1.76M
Dec 02, 2025	177.32	180.55	174.53	180.18	1.85M
Dec 01, 2025	180.15	181.78	175.88	177.78	1.94M
Nov 28, 2025	182.07	182.74	180.69	182.09	566.36K
Nov 26, 2025	181.96	183.93	180.76	181.94	1.48M
Nov 25, 2025	177.07	182.97	176.09	181.96	2.21M
Nov 24, 2025	177.65	185.17	175.57	176.82	3.99M
Nov 21, 2025	168.54	176.02	167.42	175.30	2.25M
Nov 20, 2025	168.15	170.91	165.75	168.18	1.88M

Contact Details

Cambridge, MA 02142

United States

https://www.biogen.com 617 679 2000

About Company

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Stock Peers

AMGN

2.96+0.91%

Amgen Inc.$327.38 GILD

2.82+2.32%

Gilead Sciences, Inc.$124.29 HZNP

Horizon Therapeutics Public Limited Company$116.30 AZN

0.75+0.83%

AstraZeneca PLC$91.36 SNY

0.19+0.40%

Sanofi$48.18 SCLX

-0.26-1.78%

Scilex Holding Company$14.35 GRFS

0.1+1.12%

Grifols, S.A.$9.02 MIRA

0.02+1.24%

MIRA Pharmaceuticals, Inc.$1.63 CTOR

0.25+21.93%

Citius Oncology, Inc.$1.39 SCLXW

0.0015+0.88%

Scilex Holding Company$0.17

Company Overview

Biogen Inc. (NASDAQ:BIIB) closed at $174.70 USD, losing -$0.10 (-0.06%) from the previous close of $174.80. The stock is currently mid-range between its 52-week high and low $110.04 and $185.17. With a market capitalization of about $25.63 billion, Biogen Inc. is classified as a large-cap and shows lower-than-market volatility (beta ~0.13). Key stats such as the average daily volume over the past year has been around 2.06 million shares, in line with its 52-week average. Headquartered in Cambridge, MA, Biogen Inc. operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Christopher A. Viehbacher, the company employs approximately 7,605 people and listed since September 17, 1991. Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -1.37%, SMA50 7.27%, SMA200 24.8%). The stock’s 14-day RSI is 54.83 (neutral), while the ATR of 5.38 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -5.6% below its high and over 58.86% above its low. Average 10-day trading volume of 4.80 million shares is significantly above the 3-month average of 2.01 million, indicating heightened recent market interest.

Valuation Metrics

Biogen Inc. trades at a P/E ratio of 15.93, slightly below the S&P 500 average, with a price-to-sales ratio of 2.55 and a price-to-book ratio of 1.41 suggesting the stock is closer to book value. The P/FCF stands at 11.26, also above market averages.

Dividend & Fair Value

Biogen Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $361.76. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Biogen Inc. generated EPS of $10.97 over the past year. Five-year average earnings growth is -18.66%. Wall Street analysts project EPS growth of -1.58% annually over the next five years. The latest quarter delivered EPS of $3.17. The next quarter is forecast at $1.74. Next year's EPS is expected at $5.39. Analyst sentiment is neutral. Analyst rating data shows there are 6 Strong Buy ratings, 9 Buy ratings, 18 Hold ratings, 1 Sell rating and 0 Strong Sell ratings. Price targets range from $265.00 to $115.00. The high target offers 51.6% upside. The low target suggests -34.21% downside. The mean target is $178.06. This offers 1.86% upside. Biogen Inc. earnings surprise history is a mixed track record. The quarter that ended October 30, 2025, missed forecasts by -18.51%. The prior quarter beat by 40.26%. Over the last six quarters, Apple has recorded several small beats. These include 31.34% in August 01, 2024.

Shareholding & Insider Activity

Biogen Inc. has 146.61 million shares outstanding. The public float is 146.22 million shares, elevated short interest at 4.30% of float. This equals 4.88 million shares. The short ratio is 2.9 days. Institutional investors hold 92.7% of the float. Insiders own 0.15%. BIOGEN INC. holds 17.65 million shares, DENNER ALEXANDER J has 643.00 thousand shares and SCANGOS GEORGE A has 54.78 thousand shares. Over the past six months, insider transactions show net selling. They sold 2.74 thousand shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Biogen generated $9.84B in revenue, or $67.55 per share. Gross margin was 74.24%, operating margin 13.18%, and net profit margin 11.81%. Returns are modest, with ROA at 4.33% and ROE at 7.85%.
On valuation metrics, Biogen trades at a P/E of 15.93, P/S of 2.55 and P/B of 1.41. The current ratio is 2.72 and quick ratio is 2.04. Operationally, the company’s inventory turnover is 1.26 and cash conversion cycle is 302.76 days. Debt-to-equity is 0.36, supported by a cash flow-to-debt ratio of 0.37.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Biogen posted revenue of $9.84B, down slightly from $10.17B in the prior quarter. Gross profit was $7.30B (margin 74.24%). Operating income was $1.30B (margin 13.2%). Net income was$1.16B (EPS $8.02).
The company ended the quarter with $1.05B in cash and short-term investments, a total debt of $7.34B, and net debt of $6.29B. Total assets were $26.84B, with equity of $14.80B. Financials further reflected stability, with operating cash flow of $1.55B, free cash flow of $1.24B, and capital expenditures of - $311.40M.

Price Forecast & Outlook

Our AI price prediction model suggests that Biogen Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.78%, with price expected at $166.44 by January 02, 2026, within a range of $162.68 to $170.31 3-Month Outlook: Projected rise of 43.12%, reaching $250.17 by March 19, 2026, with a range of $245.03 to $255.77. 1-Year Outlook: Projected loss of -34.98%, with price at $113.66 by December 18, 2026, within a range of $105.20 to $121.69.

Key Takeaways

Biogen Inc. (NASDAQ:BIIB) shares are up 14.31% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Biogen Inc. trading at a premium to the broader market with a P/E of 15.93. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $260.38, suggesting 48.96% upside. Our AI forecast model points to short-term weakness (-4.78% over two weeks), a medium-term rise (43.12% over three months), and a longer-term loss (-34.98% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Biogen Inc. (BIIB) stock price?

Biogen Inc. (NASDAQ: BIIB) stock price is $174.70 in the last trading session. During the trading session, BIIB stock reached the peak price of $177.29 while $172.90 was the lowest point it dropped to. The percentage change in BIIB stock occurred in the recent session was -0.06% while the dollar amount for the price change in BIIB stock was - $0.10.

BIIB's industry and sector of operation?

The NASDAQ listed BIIB is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Biogen Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BIIB?

Ms. Nicole Murphy
Head of Pharmaceutical Operations & Technology
Dr. Sanjay Jariwala
Senior Vice President of Worldwide Medical
Ms. Robin C. Kramer
Senior Vice President & Chief Accounting Officer
Mr. Adam Keeney Ph.D.
Executive Vice President & Head of Corporation Devel.
Dr. Anabella Villalobos Ph.D.
Head of Biotherapeutics & Medicinal Sciences
Dr. Mahalakshmi Radhakrishnan M.D.
Chief Medical Officer & Group Senior Vice President
Ms. Natacha Gassenbach
Chief Communication Officer & Head of Corporation Affairs
Dr. Ginger Gregory
Executive Vice President & Chief HR Officer
Mr. Christopher A. Viehbacher
Pres, Chief Executive Officer & Director
Mr. Michael R. McDonnell CPA
Executive Vice President & Chief Financial Officer
Mr. Michael Hencke
Executive Director of Investor Relations & Investor Relations Team
Mr. Charles E. Triano
Senior Vice President & Head of Investor Relations
Ms. Susan H. Alexander Esq.
Executive Vice President, Chief Legal Officer & Sec.
Dr. Priya Singhal M.D., M.P.H.
Executive Vice President, Head of Devel. and Interim Head of Research, Global Safety & Regulatory Sciences
Ms. Alisha A. Alaimo
Pres & Head of North America

How BIIB did perform over past 52-week?

BIIB's closing price is 58.85% higher than its 52-week low of $110.04 where as its distance from 52-week high of $185.17 is -5.6%.

How many employees does BIIB have?

Number of BIIB employees currently stands at 7,605.

Link for BIIB official website?

Official Website of BIIB is: https://www.biogen.com

How do I contact BIIB?

BIIB could be contacted at phone 617 679 2000 and can also be accessed through its website. BIIB operates from 225 Binney Street, Cambridge, MA 02142, United States.

How many shares of BIIB are traded daily?

BIIB stock volume for the day was 1.7M shares. The average number of BIIB shares traded daily for last 3 months was 2.06M.

What is the market cap of BIIB currently?

The market value of BIIB currently stands at $25.63B with its latest stock price at $174.70 and 146.7M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	7605
Beta	0.13
Sales or Revenue	$9.84B
5Y Sales Change%	0.035%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

BIIB Company Profile and Key Details

Biogen

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Dividend & Fair Value

Earnings & Analyst Outlook

Valuation Metrics

Price Forecast & Outlook

Key Takeaways